Aclaris Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

How does the reported revenue growth compare to analyst expectations and prior quarters? What were the key drivers behind Aclaris Therapeutics' Q2 2025 earnings performance? What is the anticipated reaction of institutional investors and analysts to the Q2 results and corporate update? How might the sentiment score of 20 influence market perception and trading volume for ACRS? How does ACRS' financial health and liquidity position compare to its peers in the biotech sector? What potential catalysts or risks were highlighted that could influence the stock price in the short term? Did the company address any regulatory or clinical trial milestones that might affect long‑term growth prospects? What is the expected impact of the corporate update on the company's valuation multiples (e.g., P/E, EV/EBITDA)? Are there any notable changes in the company's pipeline or partnership announcements that could affect future cash flows? What guidance did the company provide for Q3 2025 and the full year, and how does it align with market forecasts?